We previously reported the promising effects of
dioscin against liver injury, but its effect on
liver fibrosis remains unknown. The present work investigated the activities of
dioscin against
liver fibrosis and the underlying molecular mechanisms.
Dioscin effectively inhibited the cell viabilities of HSC-T6, LX-2 and primary rat hepatic stellate cells (HSCs), but not hepatocytes. Furthermore,
dioscin markedly increased
peroxisome proliferator activated receptor-γ (
PPAR-γ) expression and significantly reduced a-smooth muscle actin (α-SMA), transforming growth factor-β1 (TGF-β1),
collagen α1 (I) (COL1A1) and
collagen α1 (III) (COL3A1) levels in vitro. Notably,
dioscin inhibited HSCs activation and induced apoptosis in activated HSCs. In vivo,
dioscin significantly improved
body weight and hydroxylproline,
laminin, α-SMA, TGF-β1, COL1A1 and COL3A1 levels, which were confirmed by histopathological assays.
Dioscin facilitated matrix degradation, and exhibited hepatoprotective effects through the attenuation of oxidative stress and
inflammation, in addition to exerting anti-fibrotic effects through the modulation of the TGF-β1/Smad, Wnt/β-
catenin,
mitogen-activated protein kinase (MAPK) and mitochondrial signaling pathways, which triggered the senescence of activated HSCs. In conclusion,
dioscin exhibited potent effects against
liver fibrosis through the modulation of multiple targets and signaling pathways and should be developed as a novel candidate for the treatment of
liver fibrosis in the future.